Protagonist Therapeutics, Inc.
PRTXN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Apr 1, 2026
7wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
⭐Phase 3Next
Open-label rusfertide Phase 3 Results Expected
Apr 1, 2026Open-label rusfertide46
Primary completion for Open-label rusfertide trial (NCT06033586) in Polycythemia Vera
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
Open-label rusfertide
Polycythemia Vera
Rusfertide
Polycythemia Vera
PTG-300
Hereditary Hemochromatosis
PN-943
Ulcerative Colitis Chronic Moderate
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Open-label rusfertide | Phase 3 | Polycythemia Vera | - |
Rusfertide | Phase 3 | Polycythemia Vera | - |
PTG-300 | Phase 2 | Hereditary Hemochromatosis | - |
PN-943 | Phase 2 | Ulcerative Colitis Chronic Moderate | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
PRTX News